ONCS - OncoSec Medical - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

5.605M

Cash

3.683M

Avg Qtr Burn

-6.249M

Short % of Float

8.22%

Insider Ownership

28.01%

Institutional Own.

5.83%

Qtr Updated

01/31/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
TAVO™-EP + OPDIVO® (nivolumab) Details Melanoma, Cancer	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TAVO™-EP + pembrolizumab Details Melanoma, Non-small cell lung carcinoma, Thermal burns, Rhabdomyosarcoma, Cancer	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CORVax12 (TAVO + SARS-CoV-2 spike glycoprotein) Details COVID-19, Hepatitis B vaccine, Hepatitis B	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TAVO™-EP + epacadostat + pembrolizumab Details Cancer, Head and neck cancer, Head and neck squamous cell carcinoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
TAVO™-EP + pembrolizumab Details Breast cancer, Triple-negative breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.